This approach was first validated using SB203580, a pyridinyl imidazole inhibitor of p38, which showed additional inhibition of RIPK2 in vitro and was efficacious in a Crohn's disease model in mice (Argast et al., 2005; Hollenbach et al., 2005). The gene discussed is RIPK2; the disease is Crohn disease.